India's Cadila gets approval to repurpose Hepatitis C drug for Covid-19

Published on Apr 23, 2021 03:34 PM IST

Cadila said patients given its therapy in clinical trials had shown lesser need for supplemental oxygen, which is given to seriously ill Covid-19 patients to increase its supply in the blood and lungs.

Cadila's drug, known as Pegylated Interferon alpha-2b, was originally approved for liver disease Hepatitis C.(MINT_PRINT)
Cadila's drug, known as Pegylated Interferon alpha-2b, was originally approved for liver disease Hepatitis C.(MINT_PRINT)
Reuters |

India's Cadila Healthcare Ltd has received restricted emergency use approval from local regulators to use a Hepatitis C drug as a treatment for moderate Covid-19 in adults, the drugmaker said on Friday.

The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of Covid-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.

Cadila said patients given its therapy in clinical trials had shown lesser need for supplemental oxygen, which is given to seriously ill Covid-19 patients to increase its supply in the blood and lungs.

About 91% of patients treated with the drug, branded Virafin, tested negative for Covid-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said earlier this month.

"The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management," Cadila Managing Director Sharvil Patel said. "It comes at a much-needed time for patients."

India reported the world's highest daily tally of coronavirus infections for a second day on Friday, surpassing 330,000 new cases.

Cadila's drug, known as Pegylated Interferon alpha-2b, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat Covid-19.

The company's shares reversed course following the news, and were last up 3.2% at 570 rupees in afternoon trading on the National Stock Exchange.

Get Latest India Newsalong with Latest Newsand Top Headlinesfrom India and around the world.
SHARE THIS ARTICLE ON
SHARE
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Sunday, September 25, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals